Overview
Wegovy is a brand name for semaglutide, a GLP-1 receptor agonist medication specifically approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It works by mimicking a natural hormone that targets areas of the brain involved in appetite regulation.
Current status
Wegovy is currently classified as Dormant. Dormant means there has been no significant new coverage recently.